Expression of Cyclin D1, D3, E, and P27 in Human Renal Cell Carcinoma Analysed by Tissue Microarray
Overview
Authors
Affiliations
Aberrations in the G1/S transition of the cell cycle have been observed in many malignancies and seem to be critical in the transformation process. Few studies have delineated the presence of G1/S regulatory defects and their clinical relevance in renal cell carcinoma (RCC). Therefore, we have examined the protein contents of cyclin D1, D3, E, and p27 in 218 RCCs, using tissue microarray and immunohistochemistry. The results from a subset of tumours were confirmed by Western blotting and immunohistochemical staining of regular tissue sections. Interestingly, low protein contents of cyclin D1 and p27 were associated with high nuclear grade, large tumour size, and poor prognosis for patients with conventional tumours. We further observed substantial differences in the pattern of G1/S regulatory defects between the different RCC subtypes. The majority of both conventional and papillary cases expressed p27; however, chromophobe tumours generally lacked p27 staining. In addition, conventional RCCs often expressed high cyclin D1 protein levels, while papillary RCCs exhibited high cyclin E. In summary, we have shown that G1/S regulatory defects are present in RCC and are associated with clinico-pathological parameters. The pattern of cell cycle regulatory defects also differed between RCC subtypes.
Identification and validation of NFIA as a novel prognostic marker in renal cell carcinoma.
de Alwis R, Schoch S, Islam M, Moller C, Ljungberg B, Axelson H J Pathol Clin Res. 2023; 9(4):261-272.
PMID: 36947439 PMC: 10240150. DOI: 10.1002/cjp2.316.
Mazumder S, Higgins P, Samarakoon R Cancers (Basel). 2023; 15(4).
PMID: 36831657 PMC: 9953937. DOI: 10.3390/cancers15041316.
G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression.
Zhang Q, Ni Y, Wang S, Agbana Y, Han Q, Liu W Int J Med Sci. 2022; 19(1):47-64.
PMID: 34975298 PMC: 8692124. DOI: 10.7150/ijms.58902.
Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma.
Petitprez F, Ayadi M, De Reynies A, Fridman W, Sautes-Fridman C, Job S Front Oncol. 2021; 11:643065.
PMID: 33996558 PMC: 8113694. DOI: 10.3389/fonc.2021.643065.
Markowitsch S, Schupp P, Lauckner J, Vakhrusheva O, Slade K, Mager R Cancers (Basel). 2020; 12(11).
PMID: 33121039 PMC: 7692972. DOI: 10.3390/cancers12113150.